Cytori Therapeutics Inc (CYTX) - Financial and Strategic SWOT Analysis Review

Description: Cytori Therapeutics Inc (CYTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cytori Therapeutics Inc (Cytori Therapeutics) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. Cytori has two key product lines, namely, the Celution System family which comprises medical devices for use in cosmetic and reconstructive surgery and StemSource family for use in laboratory research and stem cell banking. The company offers its products to the physicians and patients at the point-of-care by its proprietary technologies and products. The company markets its cellular therapeutics under the trade name, Cytori Cell Therapy. Cytori Therapeutics is headquartered in San Diego, California, the US.

Cytori Therapeutics Inc Key Recent Developments

Nov 16, 2016: Cytori Strengthens Global Intellectual Property Portfolio with Key Patents
Nov 14, 2016: Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma
Nov 09, 2016: Cytori Reports Third Quarter 2016 Business and Financial Results
Oct 26, 2016: Cytori Presents Scleroderma Clinical Trial Data at the 2016 American College of Rheumatology Annual Meeting
Oct 24, 2016: Cytori Publication on Cytori Cell Therapy for Combined Radiation and Thermal Injury

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Section 3 - Company's Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 - Company's Lifesciences Financial Deals and Alliances

Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Cytori Therapeutics Inc, Recent Deals Summary

Section 5 - Company's Recent Developments

Nov 16, 2016: Cytori Strengthens Global Intellectual Property Portfolio with Key Patents

Nov 14, 2016: Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma

Nov 09, 2016: Cytori Reports Third Quarter 2016 Business and Financial Results

Oct 26, 2016: Cytori Presents Scleroderma Clinical Trial Data at the 2016 American College of Rheumatology Annual Meeting

Oct 24, 2016: Cytori Publication on Cytori Cell Therapy for Combined Radiation and Thermal Injury

Sep 26, 2016: Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss

Sep 19, 2016: BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial

Aug 04, 2016: Cytori Reports Second Quarter 2016 Business and Financial Results

Jul 19, 2016: Cytori Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration

Jun 27, 2016: Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan

Section 6 - Appendix

Methodology

Ratio Definitions

About the Author

Contact Us

Disclaimer

List of Tables

Cytori Therapeutics Inc - Key Facts
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cytori Therapeutics Inc (CYTX) - Financial and Strategic SWOT Analysis Review
Web Address: http://www.researchandmarkets.com/reports/4027236/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 125</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 250</td>
</tr>
<tr>
<td>Electronic (PDF) - EnterpriseWide</td>
<td>USD 375</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: [ ] Mr   [ ] Mrs   [ ] Dr   [ ] Miss   [ ] Ms   [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address        | Ulster Bank,
                      | 27-35 Main Street,   |
                      | Blackrock,           |
                      | Co. Dublin,          |
                      | Ireland.             |

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World